NUCANA PLC-ADR (NCNA) Stock Fundamental Analysis

NASDAQ:NCNA • US67022C3043

2.1 USD
-0.04 (-2.1%)
Last: Feb 20, 2026, 08:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NCNA. NCNA was compared to 521 industry peers in the Biotechnology industry. NCNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NCNA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • NCNA had negative earnings in the past year.
  • In the past year NCNA has reported a negative cash flow from operations.
  • NCNA had negative earnings in each of the past 5 years.
  • In the past 5 years NCNA always reported negative operating cash flow.
NCNA Yearly Net Income VS EBIT VS OCF VS FCFNCNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • NCNA has a Return On Assets of -85.16%. This is in the lower half of the industry: NCNA underperforms 69.67% of its industry peers.
  • NCNA has a Return On Equity (-106.15%) which is in line with its industry peers.
Industry RankSector Rank
ROA -85.16%
ROE -106.15%
ROIC N/A
ROA(3y)-94.3%
ROA(5y)-72.74%
ROE(3y)-195.95%
ROE(5y)-136.12%
ROIC(3y)N/A
ROIC(5y)N/A
NCNA Yearly ROA, ROE, ROICNCNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NCNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NCNA Yearly Profit, Operating, Gross MarginsNCNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

5

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, NCNA has more shares outstanding
  • NCNA has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, NCNA has an improved debt to assets ratio.
NCNA Yearly Shares OutstandingNCNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
NCNA Yearly Total Debt VS Total AssetsNCNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 47.64 indicates that NCNA is not in any danger for bankruptcy at the moment.
  • NCNA's Altman-Z score of 47.64 is amongst the best of the industry. NCNA outperforms 95.97% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that NCNA is not too dependend on debt financing.
  • NCNA's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. NCNA outperforms 49.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 47.64
ROIC/WACCN/A
WACCN/A
NCNA Yearly LT Debt VS Equity VS FCFNCNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • NCNA has a Current Ratio of 4.76. This indicates that NCNA is financially healthy and has no problem in meeting its short term obligations.
  • NCNA has a Current ratio (4.76) which is comparable to the rest of the industry.
  • A Quick Ratio of 4.76 indicates that NCNA has no problem at all paying its short term obligations.
  • With a Quick ratio value of 4.76, NCNA perfoms like the industry average, outperforming 56.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.76
Quick Ratio 4.76
NCNA Yearly Current Assets VS Current LiabilitesNCNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1

3. Growth

3.1 Past

  • NCNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.87%, which is quite impressive.
EPS 1Y (TTM)99.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • NCNA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.20% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34%
EPS Next 2Y37.55%
EPS Next 3Y20.95%
EPS Next 5Y2.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NCNA Yearly Revenue VS EstimatesNCNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2029 2030 2031 2032 50M 100M 150M
NCNA Yearly EPS VS EstimatesNCNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1K -2K -3K

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NCNA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NCNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NCNA Price Earnings VS Forward Price EarningsNCNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NCNA Per share dataNCNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

  • NCNA's earnings are expected to grow with 20.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.55%
EPS Next 3Y20.95%

0

5. Dividend

5.1 Amount

  • No dividends for NCNA!.
Industry RankSector Rank
Dividend Yield 0%

NUCANA PLC-ADR

NASDAQ:NCNA (2/20/2026, 8:00:01 PM)

2.1

-0.04 (-2.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-18
Inst Owners2.48%
Inst Owner Change0.08%
Ins Owners0%
Ins Owner ChangeN/A
Market Cap801.39M
Revenue(TTM)N/A
Net Income(TTM)-27.52M
Analysts82.5
Price TargetN/A
Short Float %0.06%
Short Ratio2.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 22.93
P/tB 25.05
EV/EBITDA N/A
EPS(TTM)-69.02
EYN/A
EPS(NY)-1.64
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS0.09
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.16%
ROE -106.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-94.3%
ROA(5y)-72.74%
ROE(3y)-195.95%
ROE(5y)-136.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.63%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.76
Quick Ratio 4.76
Altman-Z 47.64
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)70.01%
Cap/Depr(5y)101.29%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y34%
EPS Next 2Y37.55%
EPS Next 3Y20.95%
EPS Next 5Y2.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.45%
OCF growth 3YN/A
OCF growth 5YN/A

NUCANA PLC-ADR / NCNA FAQ

What is the ChartMill fundamental rating of NUCANA PLC-ADR (NCNA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NCNA.


What is the valuation status of NUCANA PLC-ADR (NCNA) stock?

ChartMill assigns a valuation rating of 1 / 10 to NUCANA PLC-ADR (NCNA). This can be considered as Overvalued.


Can you provide the profitability details for NUCANA PLC-ADR?

NUCANA PLC-ADR (NCNA) has a profitability rating of 0 / 10.